182 related articles for article (PubMed ID: 38698538)
1. High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond.
Edsjö A; Russnes HG; Lehtiö J; Tamborero D; Hovig E; Stenzinger A; Rosenquist R;
J Intern Med; 2024 Jun; 295(6):785-803. PubMed ID: 38698538
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging sequencing-based tools for precision cancer medicine.
Edsjö A; Gisselsson D; Staaf J; Holmquist L; Fioretos T; Cavelier L; Rosenquist R
Mol Aspects Med; 2024 Apr; 96():101250. PubMed ID: 38330674
[TBL] [Abstract][Full Text] [Related]
3. Pediatric oncology enters an era of precision medicine.
Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
[TBL] [Abstract][Full Text] [Related]
4. Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients.
Hernandez-Martinez JM; Sánchez-Reyes R; De la Garza-Salazar JG; Arrieta O
Adv Exp Med Biol; 2019; 1168():79-90. PubMed ID: 31713165
[TBL] [Abstract][Full Text] [Related]
5. The Architecture of a Precision Oncology Platform.
Laganà A
Adv Exp Med Biol; 2022; 1361():1-22. PubMed ID: 35230680
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiling in oncology clinical practice.
Rodríguez N; Viñal D; Rodríguez-Cobos J; De Castro J; Domínguez G
Clin Transl Oncol; 2020 Sep; 22(9):1430-1439. PubMed ID: 31981077
[TBL] [Abstract][Full Text] [Related]
7. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
8. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N
ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877
[TBL] [Abstract][Full Text] [Related]
9. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomics and solid tumors: The next frontier in precision cancer medicine.
Tsimberidou AM; Fountzilas E; Bleris L; Kurzrock R
Semin Cancer Biol; 2022 Sep; 84():50-59. PubMed ID: 32950605
[TBL] [Abstract][Full Text] [Related]
11. Molecular Tumor Boards in Clinical Practice.
Luchini C; Lawlor RT; Milella M; Scarpa A
Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
[TBL] [Abstract][Full Text] [Related]
12. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
[TBL] [Abstract][Full Text] [Related]
13. The importance of precision medicine in modern molecular oncology.
Wang Y; Zheng D
Clin Genet; 2021 Sep; 100(3):248-257. PubMed ID: 33997970
[TBL] [Abstract][Full Text] [Related]
14. Enabling Precision Oncology Through Precision Diagnostics.
Brown NA; Elenitoba-Johnson KSJ
Annu Rev Pathol; 2020 Jan; 15():97-121. PubMed ID: 31977297
[TBL] [Abstract][Full Text] [Related]
15. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
16. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
Samsom KG; Bosch LJW; Schipper LJ; Roepman P; de Bruijn E; Hoes LR; Riethorst I; Schoenmaker L; van der Kolk LE; Retèl VP; Frederix GWJ; Buffart TE; van der Hoeven JJM; Voest EE; Cuppen E; Monkhorst K; Meijer GA
BMC Med Genomics; 2020 Nov; 13(1):169. PubMed ID: 33167975
[TBL] [Abstract][Full Text] [Related]
17. Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
[TBL] [Abstract][Full Text] [Related]
18. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
19. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
20. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
